Proffitt & Goodson Inc. reduced its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 9,669 shares of the financial services provider’s stock after selling 566 shares during the quarter. Proffitt & Goodson Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $1,179,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Ruggie Capital Group increased its position in shares of iShares Nasdaq Biotechnology ETF by 1.2% in the 2nd quarter. Ruggie Capital Group now owns 37,489 shares of the financial services provider’s stock valued at $4,117,000 after purchasing an additional 441 shares during the last quarter. Northstar Group Inc. increased its position in shares of iShares Nasdaq Biotechnology ETF by 5.5% in the 2nd quarter. Northstar Group Inc. now owns 8,680 shares of the financial services provider’s stock valued at $920,000 after purchasing an additional 450 shares during the last quarter. Bartlett & Co. LLC increased its position in shares of iShares Nasdaq Biotechnology ETF by 4.5% in the 3rd quarter. Bartlett & Co. LLC now owns 10,736 shares of the financial services provider’s stock valued at $1,309,000 after purchasing an additional 462 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in shares of iShares Nasdaq Biotechnology ETF by 0.8% in the 2nd quarter. CIBC Private Wealth Group LLC now owns 60,936 shares of the financial services provider’s stock valued at $6,692,000 after purchasing an additional 467 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of iShares Nasdaq Biotechnology ETF by 0.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 76,623 shares of the financial services provider’s stock valued at $8,415,000 after purchasing an additional 469 shares during the last quarter. Hedge funds and other institutional investors own 66.39% of the company’s stock.

Shares of NASDAQ:IBB opened at $102.18 on Wednesday. iShares Nasdaq Biotechnology ETF has a 1-year low of $100.22 and a 1-year high of $122.97.

TRADEMARK VIOLATION WARNING: “iShares Nasdaq Biotechnology ETF (IBB) Stake Lowered by Proffitt & Goodson Inc.” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/11/21/ishares-nasdaq-biotechnology-etf-ibb-stake-lowered-by-proffitt-goodson-inc.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: How to Invest in the Dividend Aristocrat Index

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.